AD26.COV2.S vaccine provides protection against Covid-19
1. The AD26.COV2.S vaccine provided protection against moderate to severe-critical Covid-19. 2. The AD26.COV2.S vaccine provided protection against severe Covid-19 ...
Tag: vaccine
COVID-19 infection risk increases as the time elapsed since receiving a 2nd dose of Pfizer vaccine increases
1. In a retrospective cohort study, compared to the risk in the initial 90 days after receiving a 2nd dose, ...
No Difference in Antibody or Humoral Responses Among Kidney Transplant Recipients Vaccinated with a 3rd Dose of mRNA or Adenovirus Vector Vaccine
1. In kidney transplant recipients (KTRs) who had no antibody response after a 2nd mRNA COVID-19 vaccine dose, there was ...
Third dose of BNT162b2 COVID-19 vaccine effective at decreasing risk of hospitalization
1. Compared to two doses of the BNT162b2 vaccine, a third booster dose was estimated to be 93% effective against ...
#VisualAbstract: Adequate antibody response to mRNA-1273 COVID-19 vaccine occurs in patients with cancer
1. The majority of patients being treated for solid tumour cancers were adequate responders to the vaccine. 2. Serious adverse ...
Risk of Guillain-Barré Syndrome following recombinant zoster vaccine in medicare beneficiaries
1. In a cohort of Medicare beneficiaries, the recombinant zoster vaccine was associated with a slightly increased risk of Guillain-Barré ...
Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination
1. Out of 5,150,310 individuals in England that received two COVID-19 vaccine doses, 81 patients passed away from COVID-19 and 71 were ...
Routine childhood vaccinations disrupted by the 2020 global pandemic
1. Approximately 8.5 million children were estimated to have missed DTP3 and MCV1 vaccinations in 2020 due to the global ...
COVID-19 vaccinations during pregnancy: coverage and safety
1. In a cohort of pregnant women in the United Kingdom, COVID-19 vaccines did not alter perinatal outcomes. Evidence Rating ...
#VisualAbstract: Novel malaria vaccine candidate (R21/MM) is safe and highly protective against malaria transmission in African children
1. Vaccine efficacy at 6 months for R21/MM was 74% in group 1 and 77% in group 2. 2. R21/MM showed ...
